Stephan Stilgenbauer

Stephan Stilgenbauer is a leading CLL geneticist who has contributed fundamentally to understanding the role of chromosomal deletions and mutations, particularly del(17p) and TP53 mutation, in CLL prognosis and treatment selection. His laboratory characterized the genetic landscape of CLL and demonstrated that patients with TP53 dysfunction benefit specifically from BCL-2 inhibition with venetoclax rather than chemotherapy. He has been a co-investigator on venetoclax registration trials and has led major GCLLSG studies. He serves on EMA committees and international CLL guideline panels.